Self-Assessment and Management for Chemotherapy-Induced Taste Changes
(TAS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the effectiveness of different methods for detecting and managing taste changes in individuals starting chemotherapy. It aims to determine whether a self-assessment tool (Taste Alteration Self-Assessment) identifies taste changes more effectively than standard care and whether it leads to better management, maintaining stable food intake. Participants will be divided into two groups: one will receive standard care, while the other will use the tool to track and manage taste changes. Individuals beginning chemotherapy for common cancer types who can communicate in English may be suitable for this study. As an unphased trial, this study provides a unique opportunity to enhance care for future patients experiencing taste changes during chemotherapy.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this self-assessment and management protocol is safe for managing chemotherapy-induced taste changes?
Research shows that changes in taste commonly affect cancer patients undergoing chemotherapy. These changes can alter food perception, leading to reduced appetite and food dislikes. Studies have found that the Chemotherapy-induced Taste Alteration Scale (CiTAS) effectively identifies and manages these taste changes.
In previous studies with cancer patients, the CiTAS tool checked for taste changes without causing significant harm or discomfort. This tool helps patients notice and track taste changes and provides guidance on managing them. The process has been well-received, with no reports of serious side effects from this self-assessment and management method.
In summary, past research indicates that the taste alteration self-assessment and management approach is safe. It helps patients manage taste changes without introducing new risks.12345Why are researchers excited about this trial?
Researchers are excited about the Taste Alteration Self-Assessment because it empowers patients to actively manage their chemotherapy-induced taste changes. Unlike the standard care that offers general advice, this new approach uses a specific assessment tool called the Chemotherapy-induced Taste Alterations Scale (CiTAS). This tool helps patients identify the severity of their taste changes and select tailored interventions based on evidence. The hands-on involvement and personalized strategies could lead to more effective management of taste alterations, enhancing patients' quality of life during chemotherapy.
What evidence suggests that this trial's treatments could be effective for managing chemotherapy-induced taste changes?
Research has shown that changes in taste are common after chemotherapy and can significantly affect patients' eating habits. One study found that 38% to 77% of cancer patients experienced noticeable taste changes following chemotherapy, which can lead to poor nutrition and other health issues. In this trial, participants in the "Treatment - TA Self-monitoring and Self-management" arm will use the Chemotherapy-induced Taste Alterations Scale (CiTAS) to identify taste changes and apply self-care strategies, such as eating milder foods or improving oral care, to manage these symptoms more effectively. By using these assessments and strategies, patients may reduce the impact of taste changes and maintain better eating habits. Meanwhile, participants in the "Control/Usual Care" arm will receive standard care with additional evaluation of taste alteration severity.15678
Who Is on the Research Team?
Mary L Hook, PhD, RN
Principal Investigator
Aurora Sinai Medical Center
Are You a Good Fit for This Trial?
This trial is for individuals experiencing taste changes due to chemotherapy. Participants must be starting their initial chemotherapy and willing to complete assessments, engage in self-management, and work with nurse coaches. Specific details on inclusion or exclusion criteria are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment and Education
Participants complete baseline assessment and receive patient education based on assigned intervention (usual care vs. treatment) before starting chemotherapy
Chemotherapy and Intervention
Participants engage in TA management between chemotherapy infusion clinic visits, complete TA assessments, and work with nurse coaches
Data Collection and Continued Intervention
Complete study data collection on the 4th chemotherapy cycle and continue intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment, with final data collection at 6 months
What Are the Treatments Tested in This Trial?
Interventions
- Taste Alteration Self-Assessment
- Taste Alteration Self-Management
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor